FGF21 Restores Hepatic Leptin Sensitivity and Enhances Metabolic Benefits in Obesity: Hepatology | September 2026
Introduction:
Leptin has powerful metabolic effects, but leptin resistance in obesity limits its therapeutic potential. This study shows that FGF21 can restore peripheral leptin sensitivity, creating a synergistic effect against obesity-related metabolic disease.
How Does FGF21 Restore Leptin Sensitivity?
FGF21 acts on adipose tissue to increase adiponectin, which subsequently activates STAT1 signaling in hepatocytes and increases functional hepatic leptin receptors.
FGF21 → adiponectin ↑ → STAT1 activation → hepatic leptin receptor ↑ → leptin sensitivity restored
Human hepatocytes and liver organoids supported this mechanism: adiponectin, rather than FGF21 directly, reversed lipotoxic suppression of leptin receptors.
What Happened With Dual FGF21–Leptin Therapy?
In obese mice, combined FGF21 and leptin produced substantially greater improvements than either hormone alone, including:
Reduced weight gain and adiposity
Improved insulin resistance and hyperglycemia
Improved dyslipidemia
Near-complete resolution of hepatic steatosis
Normalization of liver injury markers
Interestingly, these benefits occurred without reducing food intake, suggesting important peripheral metabolic effects.
Clinical Impact:
FGF21 analogues are already being investigated for MASH and metabolic disease, but their effects on weight and glycemic control can be limited. Restoring leptin sensitivity may provide a complementary strategy to broaden their metabolic benefits.
Caution:
These findings are predominantly preclinical, based on animal models and human hepatocytes/organoids. Clinical efficacy and safety of FGF21–leptin dual agonism remain to be established.
Bottom Line:
FGF21 may overcome obesity-related hepatic leptin resistance through an adiponectin–STAT1 pathway. Dual FGF21–leptin agonism could therefore represent a future strategy targeting obesity, insulin resistance, dyslipidemia and MASLD simultaneously.
